A Case of Retinal Tear Associated with Use of Sorafenib

Inhibition of angiogenesis is a target in the treatment of a variety of malignancies. Sorafenib is an oral inhibitor of multiple tyrosine kinases involved in tumor angiogenesis. A related case of ophthalmologic toxicity has been reported with another vascular endothelial growth factor receptor inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaertner, Kelly M., Caldwell, Stephen H., Rahma, Osama E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109517/
https://www.ncbi.nlm.nih.gov/pubmed/25105094
http://dx.doi.org/10.3389/fonc.2014.00196
_version_ 1782327883409129472
author Gaertner, Kelly M.
Caldwell, Stephen H.
Rahma, Osama E.
author_facet Gaertner, Kelly M.
Caldwell, Stephen H.
Rahma, Osama E.
author_sort Gaertner, Kelly M.
collection PubMed
description Inhibition of angiogenesis is a target in the treatment of a variety of malignancies. Sorafenib is an oral inhibitor of multiple tyrosine kinases involved in tumor angiogenesis. A related case of ophthalmologic toxicity has been reported with another vascular endothelial growth factor receptor inhibitor, sunitinib. We report the first case of retinal tear possibly associated with sorafenib.
format Online
Article
Text
id pubmed-4109517
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-41095172014-08-07 A Case of Retinal Tear Associated with Use of Sorafenib Gaertner, Kelly M. Caldwell, Stephen H. Rahma, Osama E. Front Oncol Oncology Inhibition of angiogenesis is a target in the treatment of a variety of malignancies. Sorafenib is an oral inhibitor of multiple tyrosine kinases involved in tumor angiogenesis. A related case of ophthalmologic toxicity has been reported with another vascular endothelial growth factor receptor inhibitor, sunitinib. We report the first case of retinal tear possibly associated with sorafenib. Frontiers Media S.A. 2014-07-24 /pmc/articles/PMC4109517/ /pubmed/25105094 http://dx.doi.org/10.3389/fonc.2014.00196 Text en Copyright © 2014 Gaertner, Caldwell and Rahma. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Gaertner, Kelly M.
Caldwell, Stephen H.
Rahma, Osama E.
A Case of Retinal Tear Associated with Use of Sorafenib
title A Case of Retinal Tear Associated with Use of Sorafenib
title_full A Case of Retinal Tear Associated with Use of Sorafenib
title_fullStr A Case of Retinal Tear Associated with Use of Sorafenib
title_full_unstemmed A Case of Retinal Tear Associated with Use of Sorafenib
title_short A Case of Retinal Tear Associated with Use of Sorafenib
title_sort case of retinal tear associated with use of sorafenib
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109517/
https://www.ncbi.nlm.nih.gov/pubmed/25105094
http://dx.doi.org/10.3389/fonc.2014.00196
work_keys_str_mv AT gaertnerkellym acaseofretinaltearassociatedwithuseofsorafenib
AT caldwellstephenh acaseofretinaltearassociatedwithuseofsorafenib
AT rahmaosamae acaseofretinaltearassociatedwithuseofsorafenib
AT gaertnerkellym caseofretinaltearassociatedwithuseofsorafenib
AT caldwellstephenh caseofretinaltearassociatedwithuseofsorafenib
AT rahmaosamae caseofretinaltearassociatedwithuseofsorafenib

Ejemplares similares